No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir
暂无分享,去创建一个
V. Calvez | C. Charpentier | Y. Yazdanpanah | D. Descamps | V. Joly | R. Landman | E. Todesco | B. Visseaux | A. Marcelin | Marine Perrier